ArteraAI and Movember Announce New Relationship
“We are privileged to stand shoulder to shoulder with industry leaders in the battle against prostate cancer,” said Andre Esteva, CEO and co-founder of ArteraAI.
- “We are privileged to stand shoulder to shoulder with industry leaders in the battle against prostate cancer,” said Andre Esteva, CEO and co-founder of ArteraAI.
- The study successfully validated ArteraAI's prognostic model in advanced prostate cancer, demonstrating stronger prognostic correlations than individual clinical factors.
- ArteraAI looks forward to its continued work with these organizations as there are several ongoing initiatives in the early development phase.
- For more information on ArteraAI, visit Artera.ai .